Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded to “Strong-Buy” by StockNews.com

StockNews.com upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a buy rating to a strong-buy rating in a research report report published on Wednesday morning.

Other research analysts have also recently issued reports about the company. TD Cowen boosted their target price on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a buy rating in a research note on Tuesday, July 23rd. Cantor Fitzgerald reiterated a neutral rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, September 16th. Morgan Stanley dropped their target price on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an overweight rating on the stock in a report on Thursday, July 11th. Leerink Partners reaffirmed a market perform rating and issued a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an overweight rating in a research report on Friday, August 2nd. One analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of Moderate Buy and an average price target of $1,119.00.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $1,015.67 on Wednesday. The firm’s 50 day simple moving average is $1,118.02 and its 200 day simple moving average is $1,038.90. Regeneron Pharmaceuticals has a fifty-two week low of $769.19 and a fifty-two week high of $1,211.20. The company has a market capitalization of $111.91 billion, a price-to-earnings ratio of 30.01, a P/E/G ratio of 3.45 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same period last year, the business posted $8.79 earnings per share. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals will post 37.82 earnings per share for the current year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares in the company, valued at $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Large investors have recently modified their holdings of the stock. Creative Planning raised its holdings in Regeneron Pharmaceuticals by 22.7% in the 3rd quarter. Creative Planning now owns 11,793 shares of the biopharmaceutical company’s stock valued at $12,397,000 after acquiring an additional 2,178 shares during the period. Procyon Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 6.5% during the third quarter. Procyon Advisors LLC now owns 4,025 shares of the biopharmaceutical company’s stock worth $4,231,000 after acquiring an additional 244 shares during the period. Woodstock Corp grew its position in shares of Regeneron Pharmaceuticals by 11.7% in the third quarter. Woodstock Corp now owns 5,160 shares of the biopharmaceutical company’s stock valued at $5,424,000 after purchasing an additional 541 shares during the last quarter. Gilman Hill Asset Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 0.4% during the third quarter. Gilman Hill Asset Management LLC now owns 5,145 shares of the biopharmaceutical company’s stock worth $5,409,000 after purchasing an additional 22 shares during the period. Finally, Exchange Traded Concepts LLC lifted its holdings in Regeneron Pharmaceuticals by 2.7% during the 3rd quarter. Exchange Traded Concepts LLC now owns 4,020 shares of the biopharmaceutical company’s stock worth $4,226,000 after purchasing an additional 107 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.